Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.32 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28860343 | 0.79 | PDPK1 (0.35) | SLC9A1KEAP1PDE10A | |
| SCHEMBL20356293 | 0.75 | CDK4 (0.31) | — | |
| SCHEMBL20356533 | 0.73 | HTR1A (0.33) | — | |
| SCHEMBL29790450 | 0.72 | ADORA3 (0.40) | PARP1KAT2BPDE10AGPR139 | |
| SCHEMBL29303154 | 0.72 | ELANE (0.35) | MEN1ALDH1A1KMT2ASLC9A1KEAP1 | |
| SCHEMBL13106207 | 0.72 | HSP90AB1 (0.39) | PARP1MAOBHSP90AB1MEN1ALDH1A1 | |
| SCHEMBL10129331 | 0.71 | ADORA3 (0.43) | ALDH1A1SLC9A1KEAP1 | |
| SCHEMBL8536634 | 0.69 | PARP1 (0.36) | PARP1MAOBHSP90AB1MEN1ALDH1A1 | |
| SCHEMBL20356531 | 0.67 | TYMS (0.34) | MEN1ALDH1A1KMT2AKEAP1 | |
| SCHEMBL23067956 | 0.67 | GRM4 (0.41) | MAOBALDH1A1KAT2BSLC9A1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114357-A1 | BIFUNCTIONAL PROTAC AND MOLECULAR GLUE COMPOUNDS AND METHODS OF USE THEREOF | BAERENKRAFT THERAPEUTICS, LLC | 2025-04-10 | — | — | US | disclosed |
| CN-108264512-A | Nitrogenous fused heterocyclic compound, preparation method, intermediate, composition and application | 上海医药集团股份有限公司 | 2018-07-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114357-A1 | BIFUNCTIONAL PROTAC AND MOLECULAR GLUE COMPOUNDS AND METHODS OF USE THEREOF | F12, RPP30, RPS27A | PARP1 361/4885MAOB 4454/4885HSP90AB1 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.